Providing a VOICE for Colorado's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
RMOS Educational Award
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
RMOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Ibrutinib Plus Rituximab for Rare Blood Cancer
On August 27, AbbVie announced that the FDA has approved ibrutinib (Imbruvica) (Pharmacyclics, LLC) plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL). This approval represents the first and only chemotherapy-free combination treatment specifically indicated for the disease.
Read the full AbbVie corporate press release here.
Tweets by OSSatACCC